IBA receives FDA clearance, launches new product
Ion Beam Applications (IBA) and RaySearch Laboratories AB have received FDA 510(k) clearance for their new dosimetry solution, Compass, which has been launched worldwide through IBA’s business unit IBA Dosimetry.

Pierre Mottet, chief executive officer of IBA, said that the value to this dosimetry solution is that “in advanced IMRT/IGRT treatments it can maximize the effective dose delivered to a tumor while sparing the surrounding health tissue.”

According to the Louvain-la-Neuve, Belgium-based IBA, the Compass is a state-of-the-art solution for quality assurance in radiotherapy that will enable medical staff to measure and reconstruct a 3D radiation dose delivered to a patient every day during the course of treatment.